{
    "clinical_study": {
        "@rank": "139474", 
        "arm_group": {
            "arm_group_label": "GS-5745", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive GS-5745 by intravenous (IV) infusion over approximately 30 minutes every 2 weeks."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, sequential dose-escalation, and expansion study to\n      evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone\n      and in combination with chemotherapy."
        }, 
        "brief_title": "Safety and Tolerability Study in Solid Tumors", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Tumors", 
            "Pancreatic Cancer", 
            "Non-small Cell Lung Cancer", 
            "Esophagogastric Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study consists of 2 parts (Parts A and B).  Participants can only qualify for and\n      participate in 1 part.\n\n      Part A is a sequential dose escalation to determine the maximum tolerated dose of GS-5745 in\n      participants with advanced solid tumors that are refractory to or intolerant to standard\n      therapy or for which no standard therapy exists.  In Part A, participants will receive\n      GS-5745 only.  Part A will consist of 12-54 participants.\n\n      Part B is a dose expansion to obtain additional safety and tolerability data with GS-5745 in\n      participants with pancreatic adenocarcinoma, non-small cell lung cancer, or esophagogastric\n      carcinoma.  In Part B, participants will receive GS-5745 in combination with\n      standard-of-care chemotherapy.  Part B will consist of approximately 50 participants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female > 18 years of age\n\n          2. Part A: histologically or cytologically confirmed advanced malignant solid tumor that\n             is refractory to or intolerant of standard therapy or for which no standard therapy\n             is available\n\n          3. Part B Pancreatic Adenocarcinoma:\n\n             a. Presence of histologically confirmed inoperable locally advanced or metastatic\n             pancreatic adenocarcinoma\n\n          4. Part B NSCLC:\n\n               1. Stage IIIB with malignant pleural effusion/pleural seeding or stage IV\n                  histologically confirmed NSCLC\n\n               2. Absence of known epidermal growth factor receptor (EGFR) mutation\n\n               3. Absence of known translocation or inversion events involving the ALK gene locus\n                  (resulting in EML4-ALK fusion)\n\n          5. Part B Esophagogastric Adenocarcinoma:\n\n               1. Histologically confirmed inoperable advanced gastric adenocarcinoma (including\n                  adenocarcinoma of the gastrooesophageal junction) or relapsed gastric\n                  adenocarcinoma\n\n               2. Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or\n                  metastatic lesion)\n\n          6. All acute toxic effects of any prior antitumor therapy resolved to Grade \u2264 1 before\n             the start of study drug dosing (with the exception of alopecia [Grade 1 or 2\n             permitted] and neurotoxicity [Grade 1 or 2 permitted])\n\n          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 1\n\n          8. Life expectancy of > 3 months in the opinion of the Investigator\n\n          9. Adequate organ function defined as follows:\n\n               1. Hematologic: Platelets \u2265 100 x 10^9/L; Hemoglobin \u2265 9.0 g/dL; absolute\n                  neutrophil count (ANC) \u2265 1.5 x 10^9/L\n\n               2. Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \u2264 2.5 x\n                  ULN (if liver metastases are present, \u2264 5 x ULN); Total or conjugated bilirubin\n                  \u2264 1.5 x ULN\n\n               3. Renal: Serum Creatinine \u2264 1.5 x ULN\n\n         10. Coagulation: international normalized ratio (INR) \u2264 1.6 (unless receiving\n             anticoagulation therapy).  Subjects on full-dose oral anticoagulation must be on a\n             stable dose (minimum duration 14 days).  If receiving warfarin, the subject must have\n             an INR \u2264 3.0 and no active bleeding (ie, no bleeding within 14 days prior to first\n             dose of study drug). Subjects on low molecular weight heparin will be allowed.\n\n         11. For female subjects of childbearing potential, willingness to use a\n             protocol-recommended method of contraception from the screening visit throughout the\n             study treatment period and for 90 days following the last dose of study drugs. Note:\n             A female subject is considered to be of childbearing potential unless she has had a\n             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically\n             documented ovarian failure (with serum estradiol and follicle-stimulating hormone\n             [FSH] levels within the institutional postmenopausal range and a negative serum or\n             urine Beta-HCG), or is menopausal (age > 55 years with amenorrhea for > 6 months).\n\n         12. For male subjects of childbearing potential having intercourse with females of\n             childbearing potential, willingness to use a protocol-recommended method of\n             contraception from the start of study drug, throughout the study treatment period,\n             and for 90 days following the last dose of study drugs, and to refrain from sperm\n             donation from the start of study drug, throughout the study treatment period, and for\n             90 days following the last dose of study drugs. Note: A male subject is considered\n             able to father a child unless he has had a bilateral vasectomy with documented\n             aspermia or a bilateral orchiectomy, or has ongoing testicular suppression with a\n             depot luteinizing hormone releasing hormone (LH RH) agonist (eg, goserelin acetate\n             [Zoladex\u00ae]), leuprolide acetate [Lupron\u00ae]), or triptorelin pamoate [Trelstar\u00ae]).\n\n         13. Willingness to comply with scheduled visits, drug administration plan, imaging\n             studies, laboratory tests, other study procedures, and study restrictions\n\n         14. Evidence of a personally signed informed consent form\n\n        Exclusion Criteria:\n\n          1. History or evidence of clinically significant disorder, condition, or disease that,\n             in the opinion of the Investigator and Medical Monitor would pose a risk to subject\n             safety or interfere with the study evaluations, procedures, or completion\n\n          2. Pregnant or lactating\n\n          3. Subject with known central nervous system (CNS) metastases, unless metastases are\n             treated and stable and the subject does not require systemic steroids\n\n          4. For Part B, small cell lung cancer\n\n          5. For Part B, diagnosis of pancreatic islet cell neoplasm\n\n          6. For Part B, subjects who have received prior cytotoxic chemotherapy to treat their\n             metastatic disease\n\n          7. Myocardial infarction, symptomatic congestive heart failure (New York Heart\n             Association Classification > Class II), unstable angina, or serious uncontrolled\n             cardiac arrhythmia within the last 6 months of study Day 1\n\n          8. History of major surgery within 28 days prior to enrollment\n\n          9. Serious systemic fungal, bacterial, viral, or other infection that is not controlled\n             or requires IV antibiotics\n\n         10. Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy)\n             within 28 days or 5 half-lives, whichever is shorter, of study drug dosing (6 weeks\n             for nitrosoureas, mitomycin C, or molecular agents with t\u00bd > 10 days); concurrent use\n             of hormone therapy for breast or prostate cancer is permitted\n\n         11. Clinically significant bleeding within 28 days of Day 1\n\n         12. Subjects known to be positive for human immunodeficiency virus (HIV), hepatitis C, or\n             hepatitis B"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803282", 
            "org_study_id": "GS-US-296-0101"
        }, 
        "intervention": {
            "arm_group_label": "GS-5745", 
            "description": "GS-5745 is a humanized monoclonal antibody against matrix metalloproteinase 9.", 
            "intervention_name": "GS-5745 monotherapy and in combination with chemotherapy", 
            "intervention_type": "Drug", 
            "other_name": [
                "In Part A, GS-5745 will be given alone.", 
                "In Part B, GS-5745 will be given in combination with one of the following chemotherapy regimens:", 
                "- gemcitabine and nab-paclitaxel (for pancreatic cancer)", 
                "- mFOLFOX6 (for esophagogastric cancer)", 
                "- carboplatin and pemetrexed (for lung adenocarcinoma)", 
                "- carboplatin and paclitaxel (for lung squamous cell carcinoma)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Solid Tumor", 
            "NSCLC", 
            "Pancreatic", 
            "Esophagogastric"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bobbie.parks@alabamaoncology.com", 
                    "last_name": "Bobbie Parks", 
                    "phone": "205-599-4929"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35223"
                    }, 
                    "name": "Alabama Oncology"
                }, 
                "investigator": {
                    "last_name": "Kevin Windsor, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kwill@azpoh.com", 
                    "last_name": "Kristina Will", 
                    "phone": "480-860-5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Pinnacle Oncology Hematology"
                }, 
                "investigator": {
                    "last_name": "Michael Gordon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jcoughran@cbccusa.com", 
                    "last_name": "Jami Coughran", 
                    "phone": "661-862-8548"
                }, 
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93309"
                    }, 
                    "name": "Comprehensive Blood and Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ravindranath Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lyonemoto@mednet.ucla.edu", 
                    "last_name": "Lisa Yonemoto", 
                    "phone": "310-582-4069"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "UCLA Medical Center"
                }, 
                "investigator": {
                    "last_name": "Zev Wainberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "jimartin@flcancer.com", 
                    "last_name": "Jill Martin", 
                    "phone": "941-377-9993", 
                    "phone_ext": "319"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "investigator": {
                    "last_name": "Manish Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tthorne@iuhealth.org", 
                    "last_name": "Tracy Thorne", 
                    "phone": "574-364-2439"
                }, 
                "facility": {
                    "address": {
                        "city": "Goshen", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46526"
                    }, 
                    "name": "Indiana University Health Goshen Center for Cancer Care"
                }, 
                "investigator": {
                    "last_name": "Alexander Starodub, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "has2021@med.cornell.edu.edu", 
                    "last_name": "Hayley Sacks", 
                    "phone": "646-962-9343"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Cornell University"
                }, 
                "investigator": {
                    "last_name": "Manish Shah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gina.courtney@scresearch.net", 
                    "last_name": "Gina Courtney", 
                    "phone": "615-329-6823"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Johanna Bendell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shaunita.michael@vanderbilt.edu", 
                    "last_name": "Shaunita Michael", 
                    "phone": "615-936-5795"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt"
                }, 
                "investigator": {
                    "last_name": "Jordan Berlin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "adrian.avila@Utsouthwestern.edu", 
                    "last_name": "Adrian Avila", 
                    "phone": "214-648-5107"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "UT Southwestern"
                }, 
                "investigator": {
                    "last_name": "Arthur Frankel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bryant.gordon@hci.utah.edu", 
                    "last_name": "Bryant Gordon", 
                    "phone": "801-587-4771"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Sunil Sharma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "squinsey@nwmsonline.com", 
                    "last_name": "Sue Quinsey", 
                    "phone": "253-428-8738"
                }, 
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Northwest Medical Specialties"
                }, 
                "investigator": {
                    "last_name": "Jorge Chaves, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Dung Thai, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AEs that begin on or after the first study drug administration and within 30 days after last study drug administration will be summarized by dose level (Part A) and tumor type (Part B).", 
            "measure": "Safety as evaluated by incidence of AEs, assessment of clinical laboratory test findings, physical examination, 12-lead ECG, and vital signs measurements", 
            "safety_issue": "No", 
            "time_frame": "Baseline to completion of follow up evaluation. If follow up evaluation is not completed, baseline to date of first documented progression or date of death from any cause, whichever came first"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803282"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}